Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.7200-0.1100 (-2.87%)
At close: 03:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.8300
Open3.7200
Bid3.5000 x 3200
Ask3.7200 x 1000
Day's Range3.4400 - 3.7200
52 Week Range3.1900 - 11.4800
Volume1,324
Avg. Volume3,483
Market Cap21.254M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-2.6580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Addex Announces Participation in the H.C. Wainwright Global Investment Conference

    Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at

  • GlobeNewswire

    Addex Announces Participation in the 22nd Bio€quity Europe Conference

    Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate

  • GlobeNewswire

    Addex Shareholders Approve All Resolutions at Annual General Meeting

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not atten

Advertisement
Advertisement